University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Janel R. Long-Boyle, PharmD, PhD

Janel R. Long-Boyle, PharmD, PhD

Associate Professor, Department of Clinical Pharmacy, UCSF

Cancer Center Program Memberships

Pediatric Malignancies

Research Summary

Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.

Education

University of Minnesota, Minneapolis, BS, 2000, Biochemistry
University of Minnesota, Minneapolis, PharmD, 2006, Pharmacy
University of Minnesota, Minneapolis, PhD, 2009, Experimental and Clinical Pharmacology


Professional Experience

  • 2000-2001
    Junior Scientist (full-time), Department of Medicine, University of Minnesota, Minneapolis, MN
  • 2001-2003
    Assistant Scientist (full-time), Department of Medicine, University of Minnesota, Minneapolis, MN
  • 2006-2009
    Clinical Pharmacist (part-time), Department of Pharmacy, University of Minnesota, Medical Center-Fairview, Minneapolis, MN
  • 2008-2009
    Clinical Pharmacist (part-time), Department of Pharmacy, Minneapolis, Children’s Hospitals of Minnesota, MN
  • 2010-2015
    Assistant Professor, Department of Clinical Pharmacy, UCSF
  • 2016-present
    Associate Professor, Department of Clinical Pharmacy, UCSF
  • 2016-present
    Associate Professor, Allergy, Immunology, and Bone Marrow Transplantation, UCSF

Honors & Awards

  • 2010
    Early Career Research Award, Thrasher Pediatric Research Fund
  • 2011
    Travel Award for Early Career Researchers, UCSF Academic Senate
  • 2011
    Loan Repayment Recipient (2-year contract), National Institutes of Health Pediatric LRP
  • 2012
    Gary Rifkind Research Award for Junior Faculty, UCSF School of Pharmacy
  • 2013
    Loan Repayment Recipient (renewal, 2-year contract), National Institutes of Health Pediatric LRP
  • 2017
    Mid-Career Level Travel Award, UCSF Academic Senate

Selected Publications

  1. Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, Tang X, Janssen W, Ryu BY, De Ravin SS, Weiss MJ, Youngblood B, Long-Boyle JR, Gottschalk S, Meagher MM, Malech HL, Puck JM, Cowan MJ, Sorrentino BP. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med. 2019 04 18; 380(16):1525-1534.
    View on PubMed
  2. Wang H, Jones AK, Dvorak CC, Huang L, Orchard P, Ivaturi V, Long-Boyle J. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Aug; 25(8):1603-1610.
    View on PubMed
  3. Dvorak CC, Long-Boyle J, Dara J, Melton A, Shimano KA, Huang JN, Puck JM, Dorsey MJ, Facchino J, Chang CK, Cowan MJ. Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency. Biol Blood Marrow Transplant. 2019 Jul; 25(7):1355-1362.
    View on PubMed
  4. Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J. Determination of melphalan in human plasma by UPLC-UV method. Cancer Chemother Pharmacol. 2019 May; 83(5):905-910.
    View on PubMed
  5. Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, Krtolica A, Maltepe E. Correction: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS Biol. 2019 Jan; 17(1):e3000119.
    View on PubMed
  6. Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, Krtolica A, Maltepe E. Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS Biol. 2018 10; 16(10):e2005924.
    View on PubMed
  7. Czechowicz JA, Long-Boyle JR, Rosbe KW, Mathes EF, Frieden IJ, Shimano KA. Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants. Int J Pediatr Otorhinolaryngol. 2018 Feb; 105:48-51.
    View on PubMed
  8. Spiekerkoetter E, Sung YK, Sudheendra D, Scott V, Del Rosario P, Bill M, Haddad F, Long-Boyle J, Hedlin H, Zamanian RT. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J. 2017 09; 50(3).
    View on PubMed
  9. Cowan MJ, Dvorak CC, Long-Boyle J. Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. Hematol Oncol Clin North Am. 2017 10; 31(5):809-822.
    View on PubMed
  10. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1701-1713.
    View on PubMed
  11. Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017 Apr 04; 8(14):23851-23861.
    View on PubMed
  12. Bartelink IH, Lalmohamed A, Long-Boyle JR, Boelens JJ. Busulfan after HSCT in children and young adults - Authors' reply. Lancet Haematol. 2017 03; 4(3):e103-e104.
    View on PubMed
  13. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov; 3(11):e526-e536.
    View on PubMed
  14. McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet. 2016 May; 55(5):551-93.
    View on PubMed
  15. Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Transl Res. 2016 09; 175:103-115.e4.
    View on PubMed
  16. Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, Zamanian RT. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 Jul 15; 192(2):254-7.
    View on PubMed
  17. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit. 2015 Apr; 37(2):236-45.
    View on PubMed
  18. Miyagi SJ, Long-Boyle JR. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics. Drug Metab Lett. 2015; 9(2):80-7.
    View on PubMed
  19. Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 01; 960:194-9.
    View on PubMed
  20. French D, Sujishi KK, Long-Boyle JR, Ritchie JC. Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan. Ther Drug Monit. 2014 Apr; 36(2):169-74.
    View on PubMed

Go to UCSF Profiles, powered by CTSI